<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072262</url>
  </required_header>
  <id_info>
    <org_study_id>131128</org_study_id>
    <secondary_id>2020-003408-15</secondary_id>
    <nct_id>NCT05072262</nct_id>
  </id_info>
  <brief_title>DSAEK/DMEK and Cystoid Macular Edema - the Role for Topical NSAIDs (Nepafenac) (DMEC)</brief_title>
  <acronym>DMEC</acronym>
  <official_title>A Randomized Clinical Two-arm Trial Comparing Inflammation and Cystoid Macular Edema for the Medication Regimens Postoperative Topical NSAIDs and Steroids to Only Postoperative Topical Steroids in Patients Undergoing Corneal Endothelial Transplantations (DMEC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DMEC trial is a randomized clinical two-arm trial comparing inflammation and cystoid&#xD;
      macular edema for the medication regimens postoperative topical NSAIDs and steroids to only&#xD;
      postoperative topical steroids in patients undergoing corneal endothelial transplantations&#xD;
      (DSAEK or DMEK).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central macular thickness after 4 weeks</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Measure central macular thickness (in um) on optical coherence tomography (OCT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cystoid macular edema (CME) after 4 weeks</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Determine if the patient has CME based on evaluation of macular cysts on optical coherence tomography (OCT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular inflammation</measure>
    <time_frame>Preoperatively, and 1 week, 4 weeks, 2 months and 2 years after surgery</time_frame>
    <description>Measured by laser flare meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure</measure>
    <time_frame>Preoperatively, and 1 day, 1 week, 4 weeks, 2 months and 2 years after surgery</time_frame>
    <description>Measured by tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual outcome</measure>
    <time_frame>Preoperatively, and 1 week, 4 weeks, 2 months and 2 years after surgery</time_frame>
    <description>Measure uncorrected and corrected distance visual acuity using visual acuity chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal endothelial status</measure>
    <time_frame>1 week, 4 weeks, 2 months and 2 years after surgery</time_frame>
    <description>Measure corneal endothelial cell density using microscopy instrument</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome measure (PROM)</measure>
    <time_frame>1 week, 4 weeks and 2 months after surgery</time_frame>
    <description>COMToL questionnaire for ocular medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central macular thickness (CMT)</measure>
    <time_frame>Preoperatively, and 1 week, 2 months, and 2 years after surgery</time_frame>
    <description>Measure CMT (in um) on optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cystoid macular edema (CME)</measure>
    <time_frame>Preoperatively, and 1 week, 2 months, and 2 years after surgery</time_frame>
    <description>Determine if the patient has CME based on evaluation of macular cysts on optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)</condition>
  <condition>Descemet Membrane Endothelial Keratoplasty (DMEK)</condition>
  <arm_group>
    <arm_group_label>Control (dexamethasone only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical dexamethasone 1 mg/ml (Spersadex) started the day after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study group (NSAIDs and dexamethasone)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical nepafenac (Nevanac) 3 mg/ml and dexamethasone 1 mg/ml (Spersadex) started the day after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nepafenac Ophthalmic</intervention_name>
    <description>Topical nepafenac (Nevanac) 3 mg/ml</description>
    <arm_group_label>Study group (NSAIDs and dexamethasone)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone Ophthalmic</intervention_name>
    <description>Topical dexamethasone 1 mg/ml (Spersadex)</description>
    <arm_group_label>Control (dexamethasone only)</arm_group_label>
    <arm_group_label>Study group (NSAIDs and dexamethasone)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be 18 years and older at the time of the signing of the informed&#xD;
             consent. There is no upper age limit.&#xD;
&#xD;
          -  Scheduled for DSAEK or DMEK&#xD;
&#xD;
          -  Ability to cooperate fairly well during the examinations&#xD;
&#xD;
          -  Willing to participate in the study and capable of giving informed consent, which&#xD;
             includes compliance with the requirements and restrictions in the informed consent&#xD;
             form (ICF) and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications for use of any medication (as listed in the approved SPC, e.g.&#xD;
             allergy, pregnancy, breastfeeding)&#xD;
&#xD;
          -  Pregnancy or possible pregnancy during the study period&#xD;
&#xD;
          -  Preoperative macular edema and/or ongoing treatment for macular edema&#xD;
&#xD;
          -  Re-transplantation&#xD;
&#xD;
          -  In-operated glaucoma shunt / valve (e.g. Ahmed glaucoma valve)&#xD;
&#xD;
          -  Aphakic eyes (eyes without a biological or artificial intraocular lens)&#xD;
&#xD;
          -  Loss of central vision (expected visual acuity potential after surgery below 0.1&#xD;
             Snellen)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olav Kristianslund, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophthalmology, Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olav Kristianslund, MD PhD</last_name>
    <phone>+4722118545</phone>
    <email>olakri@ous-hf.no</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Olav Kristianslund</investigator_full_name>
    <investigator_title>Principal investigator, Senior consultant MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

